



NUCLEABIOMARKERS

PRESS RELEASE

Nuclea Biomarkers, LLC
105 South Street
Pittsfield, MA 01201
Phone: (413) 298-1009
Fax: (413) 298-5114
Email: pr@nucleabiomarkers.com
www.nucleabiomarkers.com

FOR IMMEDIATE RELEASE

NUCLEA BIOMARKERS ANNOUNCES THAT IT HAS RECEIVED A NOTICE OF ALLOWANCE FOR U.S. DESIGN PATENT ON “ANTIBODY PROTEIN ANALYSIS CHIP”

Pittsfield, Massachusetts -----June 5, 2006 Nuclea Biomarkers, LLC

announced today that it has received notification from the United States Patent and Trademark Office that a Notice of Allowance has been issued for its Design Patent application entitled “Antibody Protein Analysis Chip” (US Patent Application Serial No. 29/232,958).

“We are very pleased concerning the allowance of this patent,” stated Patrick J. Muraca, Co-founder, President and CEO, of Nuclea. “Our technology allows Nuclea to accurately, reproducibly and rapidly analyze gene or protein targets, assuring reliable results when analyzing the nucleic acids for the presence of specific proteins.”

Nuclea Biomarkers, LLC is a biotechnology services company that has developed a novel technology platform to improve greatly the efficiency of drug discovery research. Using the Company’s extensive libraries of genetic, molecular, and outcomes data and data-mining services, research professionals in pharmaceutical and life sciences companies are able to focus time and money on the most promising paths for diagnosing and treating a broad range of diseases.